Journal
CLINICAL INFECTIOUS DISEASES
Volume 73, Issue 3, Pages 531-534Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciaa1176
Keywords
AVIFAVIR; favipiravir; COVID-19; SARS-CoV-2
Categories
Funding
- Russian Direct Investment Fund
- Ministry of Industry and Trade of the Russian Federation
- Skolkovo Innovation Center
Ask authors/readers for more resources
In May 2020, AVIFAVIR, an RNA polymerase inhibitor, was granted fast-track marketing authorization by the Russian Ministry of Health for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR demonstrated a 62.5% viral clearance rate within 4 days for SARS-CoV-2 patients and was shown to be safe and well-tolerated.
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available